Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus-Reference-Cited by-同舟云学术

Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus

Published:2020-05-14 Issue:15 Volume:63 Page:8046-8058
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Vendeville Sandrine¹,Tahri Abdellah¹,Hu Lili¹,Demin Samuel¹,Cooymans Ludwig¹,Vos Ann¹,Kwanten Leen¹,Van den Berg Joke¹,Battles Michael B.²,McLellan Jason S.³,Koul Anil¹,Raboisson Pierre¹,Roymans Dirk¹,Jonckers Tim H. M.¹^ORCID

Affiliation:

1. Janssen Pharmaceutica NV, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium

2. Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755, United States

3. Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00226

Reference47 articles.

1. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis